Solid Biosciences reported Q3 2025 financials showing cash reserves of \(236.1 million, extending the cash runway into H1 2027. R&D expenses increased to \)38.9 million, primarily driven by SGT-003 manufacturing and clinical costs.
The primary focus remains on positive interim data from the Phase 1⁄2 INSPIRE DUCHENNE trial for SGT-003 (DMD gene therapy), involving 23 dosed participants. Key efficacy signals observed include a 58% mean microdystrophin expression at Day 90, strongly correlating (r=0.95) with the restoration of DAPC components. Muscle injury markers showed significant reduction: C
...